The August Issuance Wave: Celestica's $3.4B Raise, Defense-Tech IPOs, and PE Exits

The Calm Before the Calendar

The VIX closed the week near 14.56, close to its year-to-date low^[1]. By that surface-level measure, nothing is happening. But the capital-markets calendar tells a different story. August — typically the quietest month for new issuance — has produced one of the largest follow-on equity raises of 2026, a defense-tech IPO seeking nearly $530 million, a wave of PE-backed secondary sales, and multiple billion-dollar buyback expansions from European and US financials. Issuers are not waiting for September.

The simplest explanation is the most likely one: when volatility is low and equity valuations are near records, the cost of issuing equity falls and the appetite for selling stock rises. The window is open because the window feels like it might not stay open. What follows is a sourced walk through the deals that define this moment, the structural backdrop, and what to watch as summer ends.

Celestica: A $3.39 Billion Signal

On August 5, Celestica Inc. (NYSE: CLS) announced a $3 billion treasury offering of common shares to fund investments across its AI infrastructure business^[2]. The deal priced at $310 per share, and underwriters exercised the full 15% greenshoe option, bringing the total to roughly 11.1 million shares and approximately $3.39 billion in net proceeds^[3]. BofA Securities, Citigroup, and TD Securities led the underwriting.

Celestica framed the raise as a response to what CEO Rob Mionis called “the strongest demand outlook in the Company’s history,” citing multi-year visibility across high-performance AI compute and data center Ethernet networking^[2]. The use-of-proceeds language is broad — working capital, capital expenditures, general corporate purposes — which is typical for a company that needs optionality rather than a single earmarked project.

This is a primary offering, meaning the company itself is issuing new shares and receiving the proceeds. That distinguishes it from the secondary sales discussed below, where existing shareholders cash out. A $3.39 billion dilutive raise at $310 per share tells you two things: Celestica believes its stock is well-valued at current levels, and its institutional shareholder base was willing to absorb over $3 billion of new supply without a visible price collapse. The offering closed on August 7^[3].

The IPO Window: Defense Tech and Chinese Listings

Lyntris (LYNX): A Defense Roll-Up Tests the Market

Lyntris Inc. plans to raise $492 million at the midpoint of its $19–$22 price range, offering 24 million shares on the NYSE under ticker LYNX^[4]. At the high end, the deal reaches $528 million. The company, assembled by Dallas-based private equity firm Trive Capital, provides sensor architecture, hardware, and data-software platforms for the US Department of Defense and allied militaries — missile defense, maritime domain awareness, and space ISR missions^[4].

A critical structural detail: approximately 80% of the shares being sold are selling-stockholder shares, not primary capital^[4]. This is a PE exit, not a growth-funding round. The market cap at the midpoint would be roughly $2.4 billion. The deal is currently on the calendar for the week of August 19^[5].

Londian Wason (FOIL): The Largest Chinese US Listing in Over a Year

Londian Wason New Energy Tech, a Shenzhen-based manufacturer of electrolytic copper foil for lithium-ion batteries, priced an upsized IPO of approximately 4.3 million ADSs at $22 per ADS — the high end of its $20–$22 range — raising $94.3 million in gross proceeds^[6]. The stock debuted on the NYSE on August 12 under ticker FOIL, opening at $26 and reaching a valuation of approximately $2 billion^[6]. Renaissance Capital noted this was the largest Chinese company IPO in the United States in over a year^[6].

The underwriters hold a 30-day option for up to 642,857 additional ADSs^[7]. Each ADS represents five ordinary shares.

Chinese Domestic Listings: Triple-Digit First-Day Gains

The same week saw extraordinary debut performance on Chinese exchanges. On August 11, three Chinese issuers completed their first trading sessions:

Source: Public Markets Review listing ledger, August 11, 2026^[7]

These are domestic Chinese listings, not US ADRs, but they matter for the global issuance picture. Chengdu Ultra Pure, which provides coating and surface-modification products for semiconductor manufacturing, closed at RMB 503 — giving it a market capitalization of approximately RMB 51.23 billion^[7]. CIQTEK, which develops high-end scientific instruments for quantum measurement and electron microscopy, raised RMB 849 million^[7].

Public Markets Review cautions that first-day gains compare the market price to the offer price and do not show how many investors received allocations, how much stock traded, or whether the price reflects stable demand^[7]. A small public float can amplify price movements, and the analysis should always be read with that caveat.

Secondaries: Private Equity Exits Accelerate

The secondary-offering calendar is where the PE exit story is most visible. Multiple sponsor-backed companies have used August’s calm to sell down positions:

• Savers Value Village (NYSE: SVV): Ares-affiliated selling stockholders sold 23 million shares at $10.25 per share in an upsized secondary that closed August 13. The company concurrently repurchased 1,021,580 shares using cash on hand^[8]. Savers received no proceeds from the selling stockholders’ sale.

• Primo Brands (NYSE: PRMB): An affiliate of One Rock Capital Partners sold 20 million shares of Class A common stock in a $489 million SEC-registered secondary offering. Primo Brands repurchased 410,340 shares from the selling stockholder at the offering price^[9]. The deal was announced August 6 and represented one of the larger PE-backed secondaries of the month.

• OPENLANE (NYSE: OPLN): Ignition Acquisition Holdings LP, a fund advised by Apax Partners, sold 8 million shares in a secondary offering priced August 11^[10]. The company itself received no proceeds.

• Replimune (Nasdaq: REPL): Unlike the others, this is a primary follow-on — the company raised approximately $150 million by issuing 9.7 million shares and pre-funded warrants at $12.06 per share^[11]. Leerink Partners, J.P. Morgan, and Cantor Fitzgerald led the underwriting. Replimune is a commercial-stage biotech developing oncolytic immunotherapies.

The pattern is clear: financial sponsors are monetizing positions while equity markets are cooperative. The concurrent buybacks at Savers and Primo Brands are a common structure that lets the company absorb some of the supply at the offering price, softening the dilution impact on public shareholders.

Buybacks: The Counterflow

While sponsors sell, corporates are buying. Several major repurchase programs were announced or expanded in the first two weeks of August:

• MetLife (NYSE: MET): New $3 billion share repurchase authorization, announced August 5, incremental to approximately $400 million remaining under the prior authorization^[12].

• Deutsche Telekom: Increased its 2026 share buyback program by up to an additional €3 billion through end of 2026, approved by the Board of Management on August 6^[12].

• HSBC Holdings: Announced a share buyback of up to $1 billion maximum consideration, commencing August 5^[12].

• Crédit Agricole: Launched a share repurchase program for up to 32 million ordinary shares, running August 10 through September 29^[12].

• Temenos (SIX: TEMN): New buyback program of up to CHF 100 million, commencing August 13^[12].

• Ahold Delhaize: Repurchased 1.75 million shares at an average price of €33.91 in the week of August 3–7, totaling €59.3 million^[12].

The buyback wave skews heavily toward European financials and telecom — mature, cash-generative businesses returning capital rather than raising it. This is the mirror image of the US IPO and follow-on calendar, where growth companies (Celestica, Replimune) and PE sponsors (Ares, One Rock, Apax, Trive) are the ones accessing the equity markets.

The Volatility Backdrop: Quiet Surface, Violent Undertow

The backdrop to all this issuance is a market that looks calm but has been anything but beneath the surface. The VIX sits near 14.56, close to its 2026 low^[1]. Yet CNBC reported that the summer has been “quietly violent” — extraordinary single-stock swings, a record spread between S&P 500 and Nasdaq 100 volatility, and a 25% pullback in semiconductor stocks that triggered the heaviest put-buying in the history of the VanEck Semiconductor ETF (SMH)^[13].

Cboe’s head of derivatives market intelligence, Mandy Xu, noted that the rally caught many traders off-guard: “People weren’t prepared for this sharp of a rally post-earnings the past few weeks. There’s definitely been a squeeze higher which is why we’re seeing the demand for upside”^[13]. The put-to-call ratio for S&P options is at its most bullish level in at least a year, but deep out-of-the-money tail-hedge puts remain in the 66th percentile of the past five years — traders are buying crash protection even as they lean long^[13].

This matters for the issuance calendar. When VIX is low but tail-hedge demand is elevated, it signals that institutional buyers are confident enough to absorb new supply (hence the Celestica raise clearing) but are simultaneously hedging against a reversal. That combination — confident but hedged — is exactly the environment in which issuers rush to get deals done before the window narrows.

The YTD IPO Picture

Renaissance Capital reports 102 IPOs priced year-to-date through early August, down 25% from the same period in 2025, with total proceeds of approximately $14.5 billion^[14]. July alone saw 8 IPOs raise a combined $29.3 billion — but that figure was dominated almost entirely by SK hynix’s $26.5 billion offering, the largest US equity offering from a foreign issuer ever^[15]. Excluding SK hynix, the month’s proceeds would have been roughly $2.8 billion, below the 10-year historical average of $4.7 billion^[15].

The Renaissance IPO Index fell 14% in July, underperforming the S&P 500’s flat return, as the rotation out of tech and AI infrastructure names weighed on recent listings^[15]. EY’s Q2 2026 Global IPO Trends report struck a more optimistic note, describing “strong 1H activity setting the stage for what could be a historic 2H 2026” while cautioning that “execution windows may be episodic and could be shaped by mega-IPOs and geopolitics”^[14].

The themes are consistent across sources: AI infrastructure and biotech dominate the pipeline, consumer names are beginning to test the waters (Jersey Mike’s $1 billion IPO in late July was the largest restaurant IPO since 2011^[14]), and defense-tech is emerging as a new sector category with the Lyntris deal.

What to Watch Next

1. Lyntris (LYNX) pricing and debut (week of August 19): Whether a defense-tech roll-up with 80% secondary shares can clear at a $2.4 billion market cap will be a referendum on investor appetite for sponsor exits at scale. Watch the final pricing relative to the $19–$22 range and first-day volume.

2. Celestica aftermarket performance: A $3.39 billion primary raise is dilutive by definition. How CLS trades in the weeks after the offering close will indicate whether the market views the capital raise as growth-enabling or share-count-diluting. The stock priced at $310 — watch whether it holds that level.

3. Londian Wason (FOIL) stabilization: After an 18% first-day pop to $26, the question for Chinese ADRs is always whether the aftermarket holds or fades. With only 4.3 million ADSs in the float, liquidity will be thin and price discovery incomplete^[7].

4. Secondary calendar depth: Savers, Primo Brands, and OPENLANE all priced in a two-week window. If more PE-backed secondaries file in late August, it confirms the sponsor-exit thesis. If the calendar goes quiet, it may mean sponsors are waiting for better prices — a signal worth monitoring.

5. VIX trajectory: The issuance wave is happening because volatility is low. If tail-hedge positioning proves prescient and VIX spikes in September, the window for new deals — IPOs and secondaries alike — could close quickly. The historical pattern is that issuance volumes correlate inversely with VIX with a one-to-two-week lag.

6. Buyback cadence from US corporates: The August announcements have been dominated by European financials and telecom. If US mega-cap tech or healthcare companies announce new repurchase programs in September, it would reinforce the corporate-capital-return theme and provide an equity-demand counterweight to the supply from IPOs and secondaries.

FN2 Research provides market commentary and educational analysis, not personalized investment advice. All deal terms and figures cited are sourced from public filings and press releases current as of August 16, 2026.